These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 31266818)
1. Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study. Namale G; Kamacooko O; Bagiire D; Mayanja Y; Abaasa A; Kilembe W; Price M; Ssemwanga D; Lunkuse S; Nanyonjo M; Ssenyonga W; Mayaud P; Newton R; Kaleebu P; Seeley J Sex Transm Infect; 2019 Sep; 95(6):405-411. PubMed ID: 31266818 [TBL] [Abstract][Full Text] [Related]
2. Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Ndahimana Jd; Riedel DJ; Mwumvaneza M; Sebuhoro D; Uwimbabazi JC; Kubwimana M; Mugabo J; Mulindabigwi A; Kirk C; Kanters S; Forrest JI; Jagodzinski LL; Peel SA; Ribakare M; Redfield RR; Nsanzimana S Trop Med Int Health; 2016 Jul; 21(7):928-35. PubMed ID: 27125473 [TBL] [Abstract][Full Text] [Related]
3. Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. Ntamatungiro AJ; Muri L; Glass TR; Erb S; Battegay M; Furrer H; Hatz C; Tanner M; Felger I; Klimkait T; Letang E; J Antimicrob Chemother; 2017 Jul; 72(7):2069-2074. PubMed ID: 28387865 [TBL] [Abstract][Full Text] [Related]
4. Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. Baumann A; Musaazi J; Kambugu A; Kälin M; Weissberg D; Ssemwanga D; Fehr J; Castelnuovo B; Sekaggya-Wiltshire C; von Braun A J Acquir Immune Defic Syndr; 2019 Apr; 80(4):481-487. PubMed ID: 30633041 [TBL] [Abstract][Full Text] [Related]
5. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study. Afrane AKA; Goka BQ; Renner L; Yawson AE; Alhassan Y; Owiafe SN; Agyeman S; Sagoe KWC; Kwara A BMC Infect Dis; 2021 Aug; 21(1):731. PubMed ID: 34340689 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic. von Braun A; Sekaggya-Wiltshire C; Bachmann N; Ssemwanga D; Scherrer AU; Nanyonjo M; Kapaata A; Kaleebu P; Günthard HF; Castelnuovo B; Fehr J; Kambugu A J Acquir Immune Defic Syndr; 2018 Aug; 78(5):566-573. PubMed ID: 29771783 [TBL] [Abstract][Full Text] [Related]
7. Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis. von Braun A; Sekaggya-Wiltshire C; Scherrer AU; Magambo B; Kambugu A; Fehr J; Castelnuovo B AIDS Res Ther; 2017 Jan; 14(1):1. PubMed ID: 28086929 [TBL] [Abstract][Full Text] [Related]
8. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613 [TBL] [Abstract][Full Text] [Related]
9. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi. Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254 [TBL] [Abstract][Full Text] [Related]
10. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R; Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603 [TBL] [Abstract][Full Text] [Related]
11. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA; Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF; Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367 [TBL] [Abstract][Full Text] [Related]
13. Incidence and predictors of virological failure among HIV infected children and adolescents receiving second-line antiretroviral therapy in Uganda, a retrospective study. Musiime-Mwase F; Nakanjako D; Kanywa JB; Nasuuna EM; Naitala R; Oceng R; Sewankambo N; Elyanu P BMC Infect Dis; 2024 Sep; 24(1):1057. PubMed ID: 39333946 [TBL] [Abstract][Full Text] [Related]
14. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. Omooja J; Nannyonjo M; Sanyu G; Nabirye SE; Nassolo F; Lunkuse S; Kapaata A; Segujja F; Kateete DP; Ssebaggala E; Bbosa N; Aling E; Nsubuga RN; Kaleebu P; Ssemwanga D J Antimicrob Chemother; 2019 Oct; 74(10):3021-3029. PubMed ID: 31257432 [TBL] [Abstract][Full Text] [Related]
15. Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Bachmann N; von Braun A; Labhardt ND; Kadelka C; Günthard HF; Sekaggya-Wiltshire C; Castelnuovo B; Kambugu A; Lejone TI; Böni J; Yerly S; Perreau M; Klimkait T; Kouyos RD; Fehr J; J Antimicrob Chemother; 2019 Feb; 74(2):468-472. PubMed ID: 30476115 [TBL] [Abstract][Full Text] [Related]
16. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337 [TBL] [Abstract][Full Text] [Related]
17. Association between smoking and lack of HIV virological suppression in a cross-sectional study of persons with HIV on antiretroviral therapy in Uganda. Tumwegamire A; Fatch R; Emenyonu NI; Lodi S; Muyindike WR; Kekibiina A; Adong J; Ngabirano C; Beesiga B; Marson K; Golabi N; Kamya M; Chamie G; Hahn JA PLoS One; 2024; 19(3):e0300508. PubMed ID: 38507431 [TBL] [Abstract][Full Text] [Related]
18. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon . Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial. Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716 [TBL] [Abstract][Full Text] [Related]
20. Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study. Mpawa H; Kwekwesa A; Amberbir A; Garone D; Divala OH; Kawalazira G; van Schoor V; Ndindi H; van Oosterhout JJ J Int AIDS Soc; 2017 Aug; 20(1):21623. PubMed ID: 28782332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]